Regeneron Pharmaceuticals Buy Hold or Sell Recommendation

REGN -- USA Stock  

Fiscal Quarter End: December 31, 2019  

Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding Regeneron Pharmaceuticals is 'Strong Buy'. Macroaxis provides Regeneron Pharmaceuticals buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding REGN positions. The advice algorithm takes into account all of Regeneron Pharmaceuticals available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from REGN buy-and-hold prospective. Additionally take a look at Regeneron Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for muliple equity instruments please use Instant Ratings tool.

Time Horizon

Risk Tolerance

Execute Advice
Sell Regeneron PharmaceuticalsBuy Regeneron Pharmaceuticals
Strong Buy


Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Piotroski F Score

Financial Leverage

For the selected time horizon Regeneron Pharmaceuticals has a risk adjusted performance of 0.1366, jensen alpha of 0.3494, total risk alpha of 0.1953, sortino ratio of 0.1796 and treynor ratio of 0.616
Macroaxis provides advice on Regeneron Pharmaceuticals to complement and cross-verify current analyst consensus on Regeneron Pharmaceuticals. Our recommendation engine determines the corporation potential to grow exclusively from the prospective of investors current risk tolerance and investing horizon. To make sure Regeneron Pharmaceuticals is not overpriced, please check all Regeneron Pharmaceuticals fundamentals including its Debt to Equity, Total Asset and the relationship between EBITDA and Earnings Per Share . Given that Regeneron Pharmaceuticals has Number of Shares Shorted of 2.23 M, we recommend you check out Regeneron Pharmaceuticals market performance and probability of bankruptcy to make sure the company can sustain itself in the current economic cycle given your recent risk tolerance and investing horizon.

Regeneron Pharmaceuticals Trading Alerts and Improvement Suggestions

About 73.0% of the company shares are owned by institutional investors
Latest headline from MacroaxisInsider: Regeneron Pharmaceuticals exotic insider transaction detected

Regeneron Pharmaceuticals current analysts recommendations

Target Median Price380.50
Target Mean Price385.23
Recommendation Mean2.40
Target High Price510.00
Number Of Analyst Opinions22
Target Low Price324.00

Regeneron Pharmaceuticals Returns Distribution Density

Mean Return0.40Value At Risk2.79
Potential Upside3.16Standard Deviation1.86
 Return Density 

Institutional Investors

Security TypeSharesValue
Capital World InvestorsCommon Shares8.2 M2.3 B
Blackrock IncCommon Shares6.3 M1.7 B
Vanguard Group IncCommon Shares6.2 M1.7 B
Harris Associates L PCommon Shares4.1 M1.1 B
Loomis Sayles Co L PCommon Shares3.6 M996.4 M
State Street CorpCommon Shares3.5 M979.2 M
Fmr LlcCommon Shares2.7 M758.3 M

Regeneron Pharmaceuticals Greeks

Alpha over DOW
Beta against DOW=0.63
Overall volatility
Information ratio =0.18

Regeneron Pharmaceuticals Volatility Alert

Regeneron Pharmaceuticals has relatively low volatility with skewness of 0.2 and kurtosis of 2.63. However, we advise all investors to independently investigate Regeneron Pharmaceuticals to ensure market all accessible information is consistent with the expectations about its upside potential and future risk-adjusted return.
 Better Than Average     
 Worse Than Average Compare Regeneron Pharmaceuticals to competition

Regeneron Pharmaceuticals Fundamental Vs Peers

FundamentalsRegeneron PharmaceuticalsPeer Average
Return On Equity23.34 (0.31) 
Return On Asset11.38 (0.14) 
Profit Margin28.13 (1.27) 
Operating Margin32.16 (5.51) 
Current Valuation38.18 B16.62 B
Shares Outstanding107.98 M571.82 M
Shares Owned by Insiders24.61 10.09 
Shares Owned by Institutions72.68 39.21 
Number of Shares Shorted2.23 M4.71 M
Price to Earning19.79 28.72 
Price to Book3.85 9.51 
Price to Sales5.33 11.42 
Revenue7.62 B9.43 B
Gross Profit4.09 B27.38 B
EBITDA2.45 B3.9 B
Net Income2.14 B570.98 M
Cash and Equivalents2.88 B2.7 B
Cash per Share26.33 5.01 
Total Debt738 M5.32 B
Debt to Equity7.00 48.70 
Current Ratio4.03 2.16 
Book Value Per Share96.15 1.93 K
Cash Flow from Operations1.31 B971.22 M
Short Ratio2.82 4.00 
Earnings Per Share18.69 3.12 
Price to Earnings To Growth1.99 4.89 
Number of Employees7.67 K18.84 K
Market Capitalization40.62 B19.03 B
Total Asset5.61 B29.47 B
Retained Earnings677.3 M9.33 B
Working Capital2.1 B1.48 B
Current Asset2.92 B9.34 B
   Regeneron Pharmaceuticals exotic insider transaction detected [view details]